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1047-185 Postprandial Lipoproteinemia Exhibits a Bimodal 
Response in Metabolic Syndrome Patients
Robert S. Rosenson, Anna Huskin, Northwestern University, Chicago, IL
Background: Metabolic syndrome is defined by abnormal fasting lipids; however post-
prandial lipemia may provide important insights regarding cardiovascular risk in these
subjects. This study evaluated postprandial lipoprotein responses in metabolic syndrome
subjects.
Methods: 43 subjects (31 M, 12 F) with fasting triglycerides > 150 mg/dL and > 2 other
NCEP criteria for the metabolic syndrome received a NCEP Step 2 diet for 6 months. A
standardized oral fat load (50 g/m2) was given. Plasma samples were collected at base-
line, 3 hours, and 8 hours after the last meal. NMR lipoprofiles were analyzed from refrig-
erated plasma. Data are reported as medians.
Results: 28 subjects had an early TG peak and 16 subjects had a late peak. The lipopro-
tein concentrations are described in the table. Late peakers were significantly older (56.9
± 7.6 vs 50.2 ± 10.3, p = 0.03), had higher fasting glucose levels (88.4 ± 12.5 vs 78.1 ±
16.5, p = 0.04), and tended to have more metabolic syndrome risk factors (p = 0.18).
Clearance of chylomicrons and large VLDL were delayed in late vs early peakers (p <
0.01 for each variable) (Table). Small LDL levels fell less rapidly in late peakers than early
peakers (p = 0.02).
Conclusion: Hypertriglyceridemic subjects with the metabolic syndrome exhibit variable
postprandial lipoprotein responses. Delayed lipoprotein clearance is associated with
older age, higher fasting glucose levels, and more metabolic syndrome risk factors. 
1047-186 Raloxifene Improves Lipoprotein, Apolipoprotein and 
Fibrinogen in Postmenopausal Osteoporotic Women 
With or Without Hypertriglyceridemia
Thomas Dayspring, Yongming Qu, Cheryl A. Keech, North Jersey Institute of 
Menopausal Lipidology, Wayne, NJ, Lilly Research Laboratories, Indianapolis, IN
Background: Raloxifene (RLX) is used for prevention and treatment of postmenopausal
osteoporosis and has positive effects on markers of cardiovascular disease, including
lipid lowering. Women with high triglycerides (hTG) are at increased risk of cardiovascu-
lar events.
Methods: We determined the effect of 3 yrs of RLX (60 or 120 mg/d) vs. placebo (PLC)
on lipoproteins, apolipoproteins and fibrinogen in women who were classified as having
hTG (>150 mg/dL) vs. normal TG (nTG, <150mg/dL) at baseline in the Multiple Out-
comes of Raloxifene Evaluation trial. A mixed model repeated measure analysis was
used.
Results: Effect of RLX compared to PLC did not depend on baseline TG status (interac-
tion P>0.1). At baseline, TG levels in hTG (n=446) vs. nTG (n=2213) groups were 204 vs.
91 mg/dL, respectively; hTG women had elevated LDL-C, non-HDL-C, total cholesterol
and low HDL-C (P<.005 vs. nTG). At 3 yrs, RLX improved LDL-C, Apo B, non-HDL-C,
Apo A1, total choelsterol and fibrinogen compared to PLC (both TG groups). RLX was
neutral on HDL-C, but increased Apo A1 compared to PLC in both TG groups. Lipopro-
tein changes occurred at the earliest time point measured (6 mo).
Conclusion: RLX was equally efficacious for nTG and hTG women in improving lipopro-
teins, apolipoproteins and fibrinogen levels.
Table 1. Mean Values (% From Baseline) for Lipoproteins and Fibrinogen at 3 Years 
*P<.01 vs. baseline, for all groups indicated
†RLX vs. PLC within TG group, P<.03
All levels expressed as mg/dL except for fibrinogen (g/L)
1047-187 Cholesterol Goal Attainment Is Associated With Lower 
Incidence of Cardiovascular Events and Cost of Care
Linus Jönsson, Fredrik Borgström, Jan Stålhammar, Evo Alemao, Donald Dongping Yin, 
Karolinska Institutet, Stockholm, Sweden
Introduction: Lowering elevated cholesterol decreases cardiovascular (CV) morbidity
and mortality. However, a majority of treated patients do not reach recommended thera-
peutic goal (LDL < 3 mmol/l and total cholesterol < 5 mmol/l according to European
guidelines). This study describes patterns of lipid-lowering therapy in Swedish primary
care and estimates rate and determinants of goal attainment and its effect on CV events
and costs of care.
Materials and Methods: Total of 9789 patients receiving lipid-lowering treatment
between 1993 and 2003 were included from 29 primary care centers in a defined geo-
graphic area. Data were gathered on health care visits, hospitalizations, lab tests, phar-
maceuticals, co-morbidity and risk factors though retrospective review of computerized
medical records and inpatient and mortality registers. Regression methods were used to
control for baseline differences and estimate event incidences and costs of care.
Results: Within first year of treatment, 4.9% patients were titrated to a higher dose, 2.9%
received an add-on drug, 0.9% had a decrease in dosage and 15.3% discontinued treat-
ment. Average reduction in LDL was 31.1% for patients treated with statin. Overall 28.5%
evaluable patients attained the lipid goals within 3 months, 29.7% within one year. Goal
attainment was significantly higher in patients with low baseline cholesterol level (OR =
0.53), older age (OR = 1.01), prior CV events (OR = 1.53), and who received dose titra-
tion or add-on treatment (OR = 2.27). Incidence of MI, stroke and revascularization pro-
cedures was 16.8, 13.4 and 8.9 per 1000 patients per year. Total annual incidence of CV
events was 155.0 and 18.2 per 1000 patients with and without prior CV events, respec-
tively. Patients who attained lipid goals had 31.4% lower incidence of subsequent events
and lower total discounted costs compared to those not attaining lipid goals (p<0.05) dur-
ing period of observation, controlling for age, gender, previous CHD and diabetes.
Conclusions: A majority (70%) of patients on current lipid management strategy do not
attain lipid goals. However, goal attainment is associated with superior outcome in terms
of reducing CV event rates and health care costs.
1047-188 The Ratio of Oxidized Low-Density to High-Density 
Lipoproteins Is an Independent Predictor of Acute 
Myocardial Infarction in Unstable Coronary Artery 
Disease
Nina Johnston, Tomas Jernberg, Bo Lagerqvist, Agneta Siegbahn, Lars Wallentin, 
University Hospital, Uppsala, Sweden
Background: Early risk stratification is essential in patients with unstable coronary artery
disease (UCAD), i.e. unstable angina or non ST-elevation myocardial infarction (MI). Oxi-
dized low-density lipoprotein (OxLDL) is involved in numerous pathophysiological mecha-
nisms in the development of the disease .The aim of this study was to examine the
prognostic value of OxLDL in this population.
Methods: OxLDL was analyzed in 432 patients with unstable angina or non ST-elevation
MI included in the FRISC II trial. End points were death and myocardial infarction after 2
years.
Results: The median level of OxLDL was 76 (25:th-75:th percentile: 63-88 U/l). The rate
of death and myocardial infarction in relation to OxLDL and the ratio of OxLDL to high-
density lipoprotein (HDL) is shown in the table below . When adjusted for known predic-
tors of adverse outcome, including age, gender, diabetes, prior myocardial infarction, ST-
segment depression, troponin T and treatment strategy (non-invasive/ invasive), the ratio
of OxLDL to HDL was independently associated to the risk of future MI, odds-ratio
(95%CI): 2.23 (1.20-4.15).
CHOL
(mmol/L)
LDL
(mmol/L)
HDL
(mmol/L)
TG
(mmol/L)
Smoking
(%)
Weight
(kg)
Baseline 5.46 3.41 1.08 2.18 34.5 83.1
End of CREP 4.16 2.30 1.12 1.64 10.6 82.0
Follow-up 4.40 2.50 1.14 1.69 12.7 83.3
Variable Early 
Peakers (3 
hours)
Late 
Peakers (8 
hours)
% 
Change
0 to 3 
hours
% 
Change
0 to 8 
hours
% 
Chan
ge
3 to 8 
hours
% 
Chan
ge
0 to 3 
hours
% Change
0 to 8 hours
% 
Chan
ge
3 to 8 
hours
p-value for 
% change
0 to 3 
hours
p-value for 
% change
0 to 8 
hours
p-value for 
% change
3 to 8 
hours
TG 55.1 11.9 -28.8 42.0 52.9 6.7 0.04 <0.01 <0.01
LDL-C 7.0 5.1 -0.6 5.5 9.1 -0.4 0.75 0.85 0.48
HDL-C -8.9 3.9 14.2 -3.1 2.1 1.6 0.10 0.49 0.05
Chylomi
crons
1342.1 151.1 -83.8 609.5 590.9 -8.8 0.27 0.04 <0.01
Large 
VLDL
128.8 42.8 -33.1 56.7 131.1 36.9 0.05 0.04 <0.01
Large 
HDL
-6.0 -6.4 3.8 -9.0 -22.2 -17.5 0.99 0.26 0.03
Small 
LDL
-9.2 -54.6 -48.2 -6.7 -9.5 -6.1 0.94 0.17 0.02
High Triglyceride Normal Triglyceride
Placebo Raloxifene (pooled) Placebo Raloxifene (pooled)
LDL-C* 158
(-2.3)
136†
(-16.5)
151
(-0.6)
135†
(-12.7)
APO B* 158
(-7.5)
145†
(-15.8)
138
(-2.9)
128†
(-11.3)
Non-HDL-C* 195
(-3.9)
173†
(-14.7)
169
(-0.6)
154†
(-10.5)
HDL-C* 49
(5.0)
51
(8.1)
65
(6.3)
65
(6.0)
APO A1 144
(1.9)
151*†
(4.3)
155
(0.2)
159†
(2.2)
Total-C 244*
(-2.5)
225*†
(-10.3)
234
(0.9)
219*†
(-6.4)
Fibrinogen 3.4
(2.9)
2.9*†
(-12.1)
3.3
(6.7)
2.9*†
(-8.9)
